德克萨斯大学安德森癌症中心博士后职位招聘
Postdoctoral positions in the field of cancer pharmacogenomics are available immediately in Dr. Xifeng Wu’s lab at The University of Texas MD Anderson Cancer Center. Fellows are being recruited for projects aimed at identifying biomarkers for the prediction of cancer treatment outcomes by integrating genetic variation information with clinical and epidemiological data utilizing our well-characterized patient populations and extensive collection of biospecimens. Dr. Wu’s research group successfully executes contemporary epidemiologic strategies across the cancer continuum by employing advanced, state-of-the-art equipment including high- and mid-throughput assay platforms for genotyping, copy number analysis, next-generation sequencing, whole-genome expression profiling, as well as microRNA and metabolome profiling. Our capabilities include single-cell and high-content analysis, FISH, telomere length and mitochondrial DNA analysis, and other cell-based phenotypic studies.
The overarching goal of Dr. Wu’s translational research program is to construct comprehensive, clinically applicable risk prediction models along the entire cancer continuum, from etiology to screening, prognosis, treatment response and survivorship. To accomplish the program’s objectives, my laboratory practices multidisciplinary research that bridges the fields of basic science, epidemiology, biostatistics, and clinical research. We devise integrative strategies that enable risk assessment, early detection and delineation of early- and late-stage clinical outcomes. Our investigations channel towards identification and validation of clinically useful prognostic and predictive biomarkers, and discovery of molecular targets with therapeutic potential. Assimilation of biomarkers with epidemiological, clinical, phenotypic, and genetic information enables development of accurate and reliable personalized cancer risk prediction models that inform clinical care and empower clinical risk stratification along the cancer care continuum. Our multifaceted and highly innovative research has yielded novel and significant findings across malignancies, including in bladder cancer, lung cancer, renal cell carcinoma, and gastrointestinal cancer.
Successful applicants will have great opportunities to collaborate with an interdisciplinary team of biologists, epidemiologists, statisticians, and clinicians, and to develop multidisciplinary knowledge and techniques in molecular and cellular biology, epidemiology, statistics, genetics, genomics, and cancer medicine.
We seek highly motivated, enthusiastic individuals who have a Ph.D. and/or M.D. degree with less than 2 years of postdoctoral experience in biochemistry, molecular biology, cellular biology, genetics, or related fields. Applications, including curriculum vitae, contact information for three references, and a brief summary of past accomplishments should be sent by regular mail or email to: Shirley Freeman, Department of Epidemiology, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center, 1155 Pressler Blvd. Box 1340, Houston, TX, 77030. Email: SMFreeman1@mdanderson.org.